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We read with great interest the paper by Giannakeas et al.
(2016) about a novel mathematical model to describe ovarian can-
cer progression, based on the assumption that a small proportion
of ovarian cancer cells are chemoresistant from the beginning. We
truly appreciated accuracy of the reported information, which stim-
ulated us to further to point out several elements, hoping to trigger a
constructive debate. As appropriately stated by the Authors, slow-
growing cancer stem cells may have inherent chemoresistance
which allows an indeﬁnite expansion, although limited due to the
tendency for stem cells to undergo asymmetric self-renewal. Never-
theless, numerous important steps of epithelial ovarian cancer
(EOC) initiation and progression may depend, at least in part, by
the interaction between different types of committed stem cells
within the ovary and the surrounding microenvironment. To date,
accumulating evidence (Smolikova et al., 2012) suggests a pivotal
role of several immune cells, including mast cells, T-cells, neutro-
phils and macrophages, in the remodeling processes after the ovula-
tion. In this regard, the possible role of ovarian stem cells in
the initiation and progression of EOC is getting growing attention:
as widely reviewed by Thompson and Mok (2009), the typical up-
regulation of pro-inﬂammatory cytokines during ovulation may
generate a local microenvironment which induce the transforma-
tion of normal ovarian epithelial cells within in the ovary; subse-
quently, these transformed ovarian epithelial cells may undergo an
immunoediting process which orchestrates the interaction between
the inﬁltrating immune cells and ovarian stromal microenviron-
ment toward the progression of EOC.
The notion that the immune system not only protects the host
against tumor formation but also shapes tumor immunogenicity is the
basis of the cancer immunoediting hypothesis, which stresses the dual
host-protective and tumor-promoting actions of immunity on develop-
ing tumors. As summarized by Schreiber et al. (2011), this mechanism
proceeds sequentially through three distinct phases termed “elimina-
tion” (the innate and adaptive immune systemswork together to detect
the presence of a developing tumor and destroy it before it becomes
clinically apparent), “equilibrium” (rare tumor cell variantsmay survive
the elimination phase and enter the equilibrium phase, in which the
adaptive immune system prevents tumor cell outgrowth and also
sculpts the immunogenicity of the tumor cells) and “escape” (tumor
cells that have acquired the ability to circumvent immune recognitionDOI of original article: http://dx.doi.org/10.1016/j.ygyno.2016.06.014.
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2352-5789/© 2016 The Authors. Published by Elsevier Inc. This is an open access article underand/or destruction emerge as progressively growing, visible tumors).
Corroborating this view, it was already demonstrated that high pres-
ence of intraepithelial CD8+ tumor-inﬁltrating lymphocytes (TILs)
(Zhang et al., 2003), low presence of FoxP3+ T regulatory cells (Tregs)
TILs (Barnett et al., 2010) and high CD8+/Treg ratio (Sato et al., 2005)
correlate with improved survival in EOC.
In addition, tumor-associated macrophages (TAM) seem to be cru-
cial in the “immunoescaping” of EOC cells: according to recent data
(Deng et al., 2015), M2 macrophages produce a selective cytokine pat-
tern which address toward the immunosuppression respect to the M1
counterpart. Not surprisingly, it was recently evidenced that ovarian
cancer drug-resistant cells promote theM2polarization ofmacrophages
through the proliferator-activated receptor γ (PPARγ)/nuclear factor-
κB (NF-κB) pathway (Deng et al., 2015). From the clinical point of
view, patients affected by EOC usually undergo satisfactory response
to the initial surgical cytoreduction and chemotherapy, although most
of them have drug-resistant recurrence later in time, that is conceivably
due to the ability of ovarian cancer drug-resistant cells to escape ﬁrst-
line chemotherapy (Laganà et al., 2015).
Recent data suggest that platinum- and taxane-based chemotherapy
for EOC can enhance anti-tumor immunity through immunogenic cell
death, resulting in increased T cell activation and tumor inﬁltration:
such effects could potentially sensitize tumors to immunotherapies, in-
cluding checkpoint blockade. In particular, neoadjuvant chemotherapy
was associated with increased densities of cytotoxic (CD3+, CD8+,
CD8+TIA-1+, PD-1+ and CD20+) TILs (Lo et al., 2016), suggesting a pos-
sible key role for immunotherapy after the “canonical” chemotherapy in
order to target drug-resistant EOC cells.
In conclusion, we appreciate the mathematical model proposed by
Giannakeas et al. (2016) and we solicit future studies about the topic
in order to clarify the role of ovarian cancer drug-resistant cells in the
initiation and progression of the disease, taking into account the role
of immune system and surrounding microenvironment and addressing
toward a tailored immune target-therapy.Declaration of interest
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